IMMUCELL CORP /DE/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $5.5M | — | -$139.7K | — | $20.1K | -$0.02 |
| Q2 FY202510-Q · 2025-06-30 | $6.4M | — | $501.9K | — | -$748.5K | $0.06 |
| Q1 FY202510-Q · 2025-03-31 | $8.1M | — | $1.4M | — | -$657.3K | $0.16 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $45.7M | $15.9M | $3.9M | $29.8M |
| Q2 FY202510-Q | $46.7M | $16.9M | — | $29.9M |
| Q1 FY202510-Q | $45.6M | $16.6M | — | $40.9M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $20.1K | -$139.7K | $2.4M | 9,045,851 |
| Q2 FY202510-Q | -$748.5K | $501.9K | $2.8M | 9,045,851 |
| Q1 FY202510-Q | -$657.3K | $1.4M | $29 | 9,045,924 |
Filings
(4)Methodology
Every figure on this page is pulled directly from IMMUCELL CORP /DE/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].